SARS-CoV-2 BNT162b2 vaccine–induced humoral response and reactogenicity in individuals with prior COVID-19 diseaseSARS-CoV-2 BNT162b2 백신 유도 체액 반응 및 이전 COVID-19 질병이 있는 개인의 반응성Clinical Medicine Published on 2022-02-222022-09-12 Journal: JCI Insight [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] accelerated Adaptive immunity antibody binding domain BNT162b2 BNT162b2 vaccine controls COVID-19 COVID-19 disease COVID-19 group dose Fever first dose greater headache Health care humoral humoral immune response Humoral response humoral responses Hypothesis IgG antibody immune immune responses individual individuals injection malaise manifested MOST mRNA vaccine Neutralizing Neutralizing activity no increase of BNT162b2 peak Pfizer protective immune response rapid increase reactogenicity Reinfection response robust SARS-CoV-2 SARS-CoV-2 BNT162b2 second dose serum serum IgG spike IgG spike receptor-binding domain supported systemic reactions Temple University tested Vaccine vaccine dose were assessed [DOI] 10.1172/jci.insight.155889 PMC 바로가기 [Article Type] Clinical Medicine
Humoral Responses and Chronic GVHD Exacerbation after COVID-19 Vaccination Post Allogeneic Stem Cell TransplantationArticle Published on 2022-02-182024-09-02 Journal: Vaccines [Category] 대상포진, [키워드] Allogeneic stem cell transplantation cGVHD COVID-19 humoral responses Immunosuppression [DOI] 10.3390/vaccines10020330 PMC 바로가기 [Article Type] Article
Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients항-CD20 요법을 받는 환자의 SARS-CoV-2 백신에 대한 체액 및 세포 면역 반응: 1342명의 환자에 대한 체계적인 검토 및 메타 분석Meta-Analysis Published on 2022-02-012022-09-12 Journal: RMD Open [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] 95% CI anti-CD20 Anti-CD20 antibodies anti-CD20 therapy antirheumatic agents Autoimmune Autoimmune disease Autoimmune diseases B cell Bern Blood cell-mediated immune cell-mediated immune response Cellular immune response circulating conducted courses COVID COVID-19 criteria develop Endpoint excluded heterogeneity high risk humoral humoral responses kidney transplant recipient limitation malignancy Meta-analysis methodology participant Patient patients patients with haematological personalised Potential proportions random-effects model receiving response rituximab SARS-CoV-2 vaccination SARS-CoV-2 vaccine searched SSRN subgroup subgroup analysis systematic review therapy treated university vaccination Vaccine Variation were assessed [DOI] 10.1136/rmdopen-2021-002036 PMC 바로가기 [Article Type] Meta-Analysis
Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2SARS-COV-2에 대한 mRNA 및 아데노 바이러스 벡터 백신에 의해 유발 된 체액 성 반응과 세포 반응 사이의 이분법Correspondence Published on 2022-01-252022-09-01 Journal: BMC Medicine [Category] SARS, 진단, 치료기술, [키워드] Ad26 Ad26.COV2.S adenoviral vector adenoviral vector vaccine adenoviral vector-based vaccines antibody Antibody binding Antigen-specific B cells Antigen-specific T cells average B cell BNT162b2 cellular response COV2.S demonstrated dichotomy Efficacy elicited Hospitalization humoral Humoral and cellular responses Humoral response humoral responses immunogenicity investigated mRNA mRNA vaccine mRNA vaccines mRNA-1273 Neutralizing antibodies neutralizing antibody no significant difference no significant differences pandemic performed protection public health raise real-world data Research responses SARS-CoV-2 SARS-CoV-2 vaccination severe disease subject subjects supplementary material T cell T cell response T cell responses Testing two groups vaccination Vaccine [DOI] 10.1186/s12916-022-02252-0 PMC 바로가기 [Article Type] Correspondence
Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infectionSARS-CoV-2 스파이크 단백질에 대한 항체 반응의 포괄적인 특성화는 경증 감염에 대한 것 이외의 추가 백신 유도 에피토프를 찾습니다.Comparative Study Published on 2022-01-242022-09-10 Journal: eLife [Category] 변종, 치료기술, 치료제, [키워드] Affect affected age Alter Analysis antibodies antibody Antibody binding antibody epitope Antibody Response Antigen Bacteria binding C-terminal domain cause chair changes in complicate Comprehensive computing conserved Control covariate COVID-19 COVID-19 pandemic disease DNA fragment dose education effective epitope Epitopes escape escape mutations experiment exposure to faculty FAM feature finding focus foundation funding fusion peptide genetic code help Howard Hughe Howard Hughes Human Humoral response humoral responses identify immune Immune escape immune system implication individual infect infected individuals Infection Infrastructure interfere Laboratory Lower majority mild infection mRNA vaccination mRNA vaccine mutant Mutation mutations NIH not affect not altered occur offered overlapping pandemic pathway Pathways pattern peptide peptides phage phages population level portion Principal component principal component analysis produced producing PROTECT Protein RBD Region regions Research residue route S1 subunit S2 subunit SARS-CoV-2 SARS-CoV-2 spike protein Scholar selected severe disease Severe infection shape small molecule Small molecules specific antibodies specific protein spike Spike protein spike-specific antibodies Spike-specific antibody Spread stick subsequent Support supported target the antibody the antibody response the RBD the S1 subunit the SARS-CoV-2 the Spike the spike protein thought triggering unique vaccinated individual vaccinated individuals vaccination Vaccine Vaccine development vaccine-induced antibodies vaccine-induced antibody variant Variation virus was performed while wild-type [DOI] 10.7554/eLife.73490 PMC 바로가기 [Article Type] Comparative Study
Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases간 질환 환자에서 SARS-COV-2 백신 접종 후 항체 반응Brief Report Published on 2022-01-212022-09-01 Journal: Viruses [Category] 진단, 치료기술, [키워드] Adequate advanced age age anti-SARS-CoV-2 anti-SARS-CoV-2 antibody Antibody titers Breakthrough infection cirrhosis coefficient Control controls correlated Efficacy Humoral response humoral responses IgG antibodies IgG antibody Immunosuppression Immunosuppressive treatment Liver disease liver diseases mRNA-based vaccine multivariable analysis Neutralizing activity no difference no differences Patient paucity of data post vaccination profiles reported response Safe SARS-CoV-2 SARS-CoV-2 vaccine seroconversion rates Side effect symptomatic vaccination [DOI] 10.3390/v14020207 PMC 바로가기 [Article Type] Brief Report
Kinetics and persistence of cellular and humoral immune responses to SARS‐CoV‐2 vaccine in healthcare workers with or without prior COVID‐19이전 COVID-19 유무에 관계없이 의료 종사자의 SARS-CoV-2 백신에 대한 세포 및 체액 면역 반응의 동역학 및 지속성Original Article Published on 2022-01-182022-09-10 Journal: Journal of Cellular and Molecular Medicine [Category] MERS, 변종, 진단, [키워드] antibody antibody levels baseline BNT162b2 BNT162b2 mRNA vaccine cellular cellular immune responses circulating viral variant conducted COVID‐19 death declining decrease descending diagnosed dose form healthcare worker Healthcare workers highest Hospitalization humoral immune response humoral responses IFN IFN‐γ IgA level IgA levels IgG antibodies immune response immune response post‐infection immune response post‐vaccination immune responses Infection Kinetics longitudinal study mRNA vaccine natural infection neutralization Neutralization assay Neutralizing activity Neutralizing antibodies new infections of BNT162b2 participant persistence preserved SARS‐CoV‐2 SARS‐CoV‐2 infection SARS‐CoV‐2 infection secretion significantly spike‐specific CD4+ T cell spike‐specific CD8+ T cell subject T‐cell the disease titre Vaccine vaccine dose Viral waning immunity [DOI] 10.1111/jcmm.17186 PMC 바로가기 [Article Type] Original Article
Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses16주 간격으로 BNT162b2 mRNA 백신 접종 후 SARS-CoV-2 스파이크에 대한 강력한 체액성 면역 반응Article Published on 2022-01-122022-09-11 Journal: Cell Host & Microbe [Category] Fulltext, SARS, 변종, 진단, [키워드] ADCC Administered analyzed BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccination BNT162b2 mRNA vaccine Cohort coronavirus COVID-19 D614G delayed mRNA vaccine regimen dose doses Efficacy elicited greater health authorities humoral humoral immune response Humoral response humoral responses IMPROVE include individual infected individual infected individuals mRNA vaccine naïve individuals naïve vaccinees neutralization public health authority question raising receiving regimen response robust SARS-CoV-2 second dose significantly significantly increased spike spike glycoproteins Strong vaccine administration vaccine dose vaccine doses vaccinees variant variants variants of concern variants of interest while [DOI] 10.1016/j.chom.2021.12.004 PMC 바로가기 [Article Type] Article
Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19BNT162b2 mRNA 백신 접종 후 세포 및 체액 기능 반응은 순진한 피험자와 COVID-19에서 회복된 피험자 사이에 세로로 다릅니다Article Published on 2022-01-112022-09-12 Journal: Cell Reports [Category] SARS, 진단, [키워드] acute respiratory syndrome analyzed antigen-specific T cell B cell BNT162b2 BNT162b2 mRNA vaccination BNT162b2 vaccine both group both groups CD4 cell-mediated response cellular Cellular responses comparable coronavirus coronavirus disease COVID-19 COVID-19-recovered cytokine cytokine production determine functional humoral humoral responses Immunoglobulin individual inverse correlation memory B memory B cell neutralization capacity neutralizing antibody proliferation reduced response SARS-CoV-2 second dose spike subject subjects T cell activation vaccination Vaccine vaccine-induced immune response variable [DOI] 10.1016/j.celrep.2021.110235 PMC 바로가기 [Article Type] Article
Persistence of Anti-SARS-CoV-2 Antibodies in Long Term Care Residents Over Seven Months After Two COVID-19 Outbreaks두 번의 COVID-19 발생 후 7개월 동안 장기 요양 시설 입소자의 항 SARS-CoV-2 항체 지속성Immunology Published on 2022-01-032022-09-11 Journal: Frontiers in Immunology [Category] MERS, 진단, 치료법, [키워드] 229E Analysis Anti-nucleocapsid antibodies anti-nucleocapsid antibody Anti-spike antibody antibody levels approved attack rate binding domain Canada Care carried changes in collected comparison COVID-19 COVID-19 outbreak cross reaction demonstrated evaluate finding Gradual HCoV HCoV-229E HCoV-HKU1 HCoV-NL63 HCoV-OC43 HKU1 human coronavirus human coronavirus (HCoV) humoral humoral immune response Humoral response humoral responses individual individuals Long long term Long term care facilities median MONITOR monitors Month multiplexed immunoassay NL63 nucleocapsid OC43 outbreak Outbreak investigation outbreak investigations Outbreaks over participant participated performed platform provided public health RBD reaction Receptor binding domain Reinfection resident SARS-CoV-2 serologic test serologic testing serologic tests serological serological survey Serological surveys seronegative seropositive seropositive individual serostatus serum serum sample serum samples Seven Spike protein Spike proteins statistical analyses statistically significant survey term the spike protein were used [DOI] 10.3389/fimmu.2021.775420 PMC 바로가기 [Article Type] Immunology